Pharmacopeia, Cephalon to develop new therapeutic products

By Elaine Rigoli

Tampa, Fla., May 23 - Pharmacopeia and Cephalon, Inc. have formed a drug-development alliance in which Cephalon will pay Pharmacopeia an up-front program access fee of $15 million.

The primary objective of the alliance is to identify active molecules and bring them forward to clinical proof of concept, yielding novel candidates for drug development in various therapeutic areas, according to a news release.

Under the agreement, Cephalon will be responsible for identifying new compounds. The companies said they will then collaborate to advance the lead compounds to clinical candidates.

Pharmacopeia will be principally responsible for medicinal chemistry and primary biology, while Cephalon will provide further biology support as required by the collaboration, the release said.

Pharmacopeia develops small-molecule therapeutics and is based in Princeton, N.J.

Cephalon, based in Frazer, Pa., is a global biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.